PaysignPAYS
Recorded

Paysign 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration32 minParticipants7

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon. My name is Diego, and I will be your conference operator today. At this time, I would like to welcome everyone to Paysign, Inc.'s third quarter 2026 earnings conference call. After the speaker's remarks, there will be a question-and-answer session. To ask a question, press star one on your telephone keypad. To remove yourself from the queue, press star two. As a reminder, this conference is being recorded. The comments on today's call regarding Paysign's financial results will be on a GAAP basis unless otherwise noted. Paysign's earnings release was disseminated to the SEC earlier today and can be found on the Investor Relations section of our website, paysign.com, which includes reconciliations of non-GAAP measures to GAAP reported amounts. Additionally, as set forth in more detail in our earnings release, I would like to remind everyone that today's call will include forward-looking statements regarding Paysign's future performance.

Operator

Actual performance could differ materially from these forward-looking statements. Information about the factors that could affect future performance as summarized at the end of Paysign's earnings release and in our recent SEC filings. Lastly, a replay of this call will be available until January 25, 2027. Please see Paysign's third quarter 2026 earnings call announcement for details on how to access the replay. It is now my pleasure to turn the call over to Mr. Mark Newcomer, President and CEO.

Mark NewcomerPresident and CEO

Please go ahead. Thank you, Diego, and good afternoon, everyone.

Mark NewcomerPresident and CEO

Thank you for joining us for Paysign's third quarter 2026 earnings call. I am Mark Newcomer, President and Chief Executive Officer. I am joined today by Jeff Baker, our Chief Financial Officer. Also with us on the call is Matt Turner, our President of Patient Affordability, and Matt Lanford, our Chief Payments Officer, both of whom will be available for Q&A following our prepared remarks. Earlier today, we reported our third quarter results, delivering record revenue, operating income, and Adjusted EBITDA. To recap the quarter, revenue grew 43% year-over-year to $30.8 million. Net income grew over 200% to $6.7 million, or $0.11 per fully diluted share. Gross margins expanded 840 basis points to 64.7% as patient affordability became a larger share of our revenue mix, growing 110% year-over-year.

Mark NewcomerPresident and CEO

We expect gross and operating margins to continue to expand as patient affordability becomes a greater part of our revenue mix. Before I get into the details, I want to put this quarter in context within the broader strategy we have been executing against. As you know, Paysign has historically been known as a payment processor primarily serving the plasma industry. We built a leading position in that business, and it remains a good one, but it is a mature market with limited growth, and the nature of payment processing is transactional. We wanted to add business lines with real growth and a more durable value proposition that leverages our existing infrastructure. Patient affordability was that first complement. Our products and services deliver measurable values to our pharmaceutical clients by helping them increase sales and save money.

Mark NewcomerPresident and CEO

Importantly, it helps patients start and stay on the treatments they need but might not otherwise be able to afford. That combination of value for the manufacturer and an outcome for the patient is what makes these relationships sticky. It also carries more attractive margins. Pairing the two gives us a better model with a cash-generative plasma business alongside a fast-growing, higher-margin business with a large and growing market. The strategy is working. You can see it in the growth, the margin expansion, and the operating leverage we delivered this quarter, and we believe it is creating real value for our shareholders. Within that context, I want to cover the plasma customer update in our release. One of our customers has informed us that it will be moving the payment processing for 113 centers to another provider, with the transition expected to be completed in the fourth quarter.

Mark NewcomerPresident and CEO

As we understand it, the customer is consolidating this business with an existing banking partner with whom it has a broader relationship. The customer has told us that the decision was not related to our service, and we remain the processor for a number of this customer's other centers. The transition has had no effect on third quarter results, and Jeff Baker will walk you through the expected fourth quarter financial impact. The plasma business continues to grow. We expect to offset the loss of these centers over the next couple of quarters with new centers from existing clients, and we are in active discussions with a couple of prospective new plasma clients. That being said, the quarter's strength was primarily driven by better-than-expected results from our patient affordability business, where revenue more than doubled year-over-year to $16.6 million, and claim volume increased approximately 55%.

Mark NewcomerPresident and CEO

That reflects the continued maturation of existing programs, new program launching, strong utilization within those programs, and our largest pharmaceutical relationships continuing to scale. We also increased the revenue per program by about 32% year-over-year to $99,524, a sign that the programs we are adding are deepening over time and not just increasing in number. In the third quarter, we launched 19 new programs, a mix of both new programs and transitions from other providers, bringing total active programs on the platform to 167. We expect to end the year with 190 to 195 programs, adding anywhere from 59 to 64 programs to the portfolio in 2026, compared with 55 programs last year. That growth reflects the confidence pharmaceutical companies are placing in our solutions and the savings we deliver for them and the patients that rely on their therapies.

Mark NewcomerPresident and CEO

During the third quarter, our platform delivered approximately $367 million in financial assistance to patients. Through the first nine months of 2026, we have now delivered more than $1.4 billion in patient benefit. Since the launch of this platform, we have supported more than $3.2 billion in financial assistance across the programs we administer. Behind those numbers are patients who can start and stay on treatments, often life-saving treatments they need. Our dynamic business rules technology is where the value we deliver to pharmaceutical clients is easiest to measure. In the third quarter alone, it insulated our clients from approximately $82.5 million in costs that copay maximizers and accumulator programs would otherwise have absorbed. Year to date, this figure is over $553 million, and since the launch of DBR, cumulative savings have surpassed $923 million.

Mark NewcomerPresident and CEO

Those savings are a large part of why clients keep expanding their relationships with us. On industry engagement, Matt Turner served on an executive panel at the Association for Value-Based Cancer Care Summit, an oncology event attended by pharmaceutical companies, prescribers, and other patient-facing professionals. The conversation around copay maximizers and accumulators reinforced what we hear from clients. The value we deliver is resonating at senior levels in the industry. in November, our team will attend the Informa Copay Congress, an important forum for manufacturers, hub partners, and policy leaders in patient affordability, where Bryan Dennison, our SVP of Sales and Products, will discuss product updates and new service offerings we will bring to market in 2027. In summary, patient affordability is the engine of our growth, and the pipeline remains robust and supports our outlook for the rest of the year and into 2027.

Mark NewcomerPresident and CEO

Turning to plasma, revenue was $13.8 million, up 7.5% from $12.9 million a year ago, as our centers delivered higher average monthly revenue per center of $8,187, up from $7,122, reflecting stronger per-center utilization. We finished the quarter serving 562 centers and expect to end the year servicing between 445 and 450 centers, reflecting the transition we discussed. We continue to pursue new plasma business from collection companies that do not use Paysign today. Despite the financial impact that the transition has had on the fourth quarter, the continued strength of patient affordability is giving us the confidence to raise our projections on some key metrics for the year-end, and Jeff will go over those in his prepared remarks. Now turning to Apherion. Apherion draws on what we have learned as a leading processor for plasma centers.

Mark NewcomerPresident and CEO

We understand the pain points these centers face, and the software available to them is largely generic rather than built for their industry. Apherion was designed to address those needs, and we believe it can give the plasma industry, from the plasma collection process to the manufacturing of the end products, a better way to streamline and operate their business. The donor management system remains under regulatory review. We recently completed in-center testing and submitted the results as part of that process, and we will update you as it progresses. Interest in the suite remains strong in both the U.S. and the E.U. We are building our European base in Dublin through our wholly owned subsidiary, Apherion Technologies Limited, to support European demand. We also see Apherion fitting the same model that has worked for us in patient affordability, with the potential for higher margins and deeper customer relationships.

Mark NewcomerPresident and CEO

To close, this quarter is a strong example of us executing successfully on our growth strategy. We built a leading position in plasma, and we recognize the need for additional growth opportunities. Patient affordability was the first of those businesses and is now driving our results with growth, expanding margins, and operating leverage. Our dynamic business rules technology protects our pharmaceutical partners from the cost of copay maximizers and accumulators, and behind the numbers are patients who can start and stay on the treatments they need. Plasma remains a dependable source of cash flow, and our experience servicing those customers is the foundation of which Apherion was built. The strength of our underlying business and our belief that we are well-positioned to capitalize on the opportunities that lie ahead give us confidence that we will continue to deliver strong, meaningful year-over-year top and bottom line growth for the foreseeable future.

Mark NewcomerPresident and CEO

With that, I'll turn it over to Jeff for additional details on our third quarter results.

Jeff BakerCFO

Thank you, Mark. Good afternoon, everyone. We delivered another strong quarter. Patient affordability's momentum carried through the third quarter, and it shows in the results. Revenue, operating margin, and net income all finished above the high end of our guidance, and operating margin more than tripled to 23.8%. For the third quarter, total revenues increased 42.6% year-over-year to $30.8 million. Pharma industry revenue led the way, increasing 109.8% year-over-year to $16.6 million. That growth was driven by continued program expansion. Over the past 12 months, we launched 62 net pharma patient affordability programs. We exited the quarter with 167 active programs. Processed claims increased approximately 55% compared to the third quarter of 2025. Average quarterly revenue per program was $99,524 in the third quarter versus $75,435 during the same period last year.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day